Related Experiment Video
Updated: May 20, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
An Insight into Decoding Drug-resistant Key Proteins, in-silico Targeting Approach and Various Inhibitory
Snigdha Bhardwaj1, Kandasamy Nagarajan1, Tulika Bhardwaj2
1KIET School of Pharmacy, KIET Group of Institutions, Ghaziabad, Delhi-NCR, 201206, India.
Reviews on Recent Clinical Trials
|May 19, 2026
Summary
This review explores Hepatitis C virus (HCV) protein targets and inhibitors for effective treatment strategies. Understanding these targets is crucial for developing new therapies to combat HCV infection globally.
Area of Science:
- Virology
- Hepatology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) causes significant global health risks, leading to liver diseases like cirrhosis and cancer.
- HCV's genetic diversity complicates treatment, with existing drugs showing limitations against all genotypes.
Purpose of the Study:
- To identify and analyze various protein targets of HCV.
- To investigate inhibitors from diverse sources for potential HCV treatment.
Main Methods:
- Comprehensive literature search of scientific databases (PubMed, Scopus, etc.) up to 2024.
- Analysis of 218 selected publications focusing on HCV proteins, treatment strategies, and inhibitors.
- In-silico meta-analysis to assess antiviral potential and drug resistance.
Main Results:
- Identified key HCV proteins (NS5B polymerase, NS3/4A protease, CD81, core proteins) as potential therapeutic targets.
- Evaluated current direct-acting antiviral treatments, noting issues with resistance, genotype specificity, and cost.
- Highlighted the potential of HCV proteins as diagnostic and prognostic biomarkers.
Conclusions:
- Understanding HCV protein targets and inhibitors is vital for advancing treatment options.
- Future research should focus on overcoming limitations of current therapies for better prevention and treatment.
- The study aims to contribute to global efforts to reduce the burden of chronic hepatitis C.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...